查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803056

2032 年抗衰老臨床試驗市場預測：按治療類型、試驗階段、生物標記類型、研究設計、目標人群、資助者類型和地區進行的全球分析

Age-Reversal Clinical Trials Market Forecasts to 2032 - Global Analysis By Therapy Type, Trial Phase, Biomarker Type, Study Design, Target Population, Sponsor Type and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球年齡逆轉臨床試驗市場預計在 2025 年價值 15.8 億美元，到 2032 年將達到 63.8 億美元，預測期內的複合年成長率為 22.0%。

抗衰老臨床試驗是專注於測試旨在減緩、停止或逆轉生物衰老的治療方法、藥物和干涉措施的科學研究。這些試驗旨在檢驗再生醫學、抗衰老藥物、基因療法和生活方式改變等方法的安全性、有效性和持久性影響。對老化生物標記、身體機能和整體健康狀況的分析可以提供寶貴的數據，從而可能在延長健康壽命、預防與年齡相關的疾病和改善整體生活品質方面取得突破。

根據美國衛生研究院的數據，大約有 720 萬 65 歲及以上的美國人患有阿茲海默症疾病。

老年人口不斷增加，對更長健康壽命的需求

全球人口老化正推動人們對逆轉老化臨床試驗的興趣。隨著長壽成為人們關注的焦點，越來越多的人正在尋求不僅能延長壽命，還能延長健康壽命的干涉措施。這些人口結構變化推動了針對細胞衰老、老化和老齡化相關衰退的治療方法的需求。臨床試驗正在擴展，以探索再生醫學、基因治療和表觀遺傳再程式化。老年人更願意參與那些有望提高活力並減輕疾病負擔的臨床試驗。人口壓力和人口老化趨勢的疊加正在推動市場成長。

缺乏有效的生物標記

如果沒有可靠的標記物，衡量治療效果和長期效益將非常困難，這會使試驗設計、監管核准和更廣泛的臨床應用變得複雜。缺乏標準化使得不同研究結果難以比較，阻礙了研究進展。此外，缺乏普遍認可的生物標記物會增加研究成本，減緩治療方法進展，並加劇投資者和醫療專業人士的懷疑，最終限制市場擴張，並延緩抗衰老創新轉化為實用醫療解決方案。

消費者對長壽解決方案的需求

在媒體報道、名人代言以及生物駭客文化興起的推動下，消費者對長壽的興趣正在飆升。從補充劑和幹細胞療法到個人化臨床試驗，消費者正在積極尋求逆轉老化的解決方案。這種需求正推動生技公司和研究機構加速開發平臺。直銷平台正在興起，用於招募臨床試驗參與者並提供早期實驗治療方法的機會。隨著認知度的提高，人們更願意在有望恢復活力的臨床試驗中投入時間和資源。市場可望從這波積極參與、注重健康的消費者浪潮中受益。

與鄰近市場的競爭

抗衰老臨床試驗面臨來自健康科技、營養補充劑和預防醫學等相關領域日益激烈的競爭。這些替代方案通常承諾提供類似的益處，但監管門檻更低，上市時間更快。消費者可能會選擇非臨床干預措施，例如穿戴式健康監測器、人工智慧主導的診斷系統或非處方長壽補充劑。這種注意力和資金的轉移可能會稀釋臨床試驗管道，並減緩創新。此外，跨行業參與者正在進入該領域，推出混合產品，模糊了受監管的臨床試驗和消費品之間的界限。這種競爭導致市場分化，並威脅臨床方法的主導地位。

COVID-19的影響：

疫情改變了臨床試驗的格局，為老化逆轉研究帶來了挑戰和機會。封鎖和醫療中斷減緩了臨床試驗的招募和方案的實施。然而，這場危機也加速了人們對免疫復原力和生物老化的興趣，使其與老化逆轉的目標相契合。遠端監控工具和分散式臨床試驗模式已廣泛普及，促進了更廣泛的參與。遠端醫療的整合使研究能夠保持連續性並收集縱向資料。整體而言，新冠疫情激發了試驗設計的創新，同時也強調了與老齡化相關的健康干預措施的迫切性。

老年病學預計將成為預測期內最大的細分市場

市場細分預計將在預測期內佔據最大的市場佔有率，因為它具有消除導致衰老和發炎的衰老細胞的潛力。精準藥物輸送、人工智慧主導的分子發現和整合體學等技術創新正在推動該領域的發展。趨勢包括BCL-2抑制劑、植物來源化合物和激酶標靶藥物的興起。試驗設計和生物標記開發的最新進展正在改善臨床結果，而人們對老年科學日益成長的興趣也吸引了監管機構的關注和生物技術公司的投資。

預計生物技術公司部門在預測期內將以最高的複合年成長率成長。

預計生物技術公司板塊將在預測期內實現最高成長率，這得益於細胞重編程、人工智慧藥物研發和多組體學整合等領域的前沿創新。新興趨勢包括以山中伸彌因子為基礎的抗衰老療法、老年基因編輯和NAD+路徑調控。自適應測試平台、精準生物標記和器官再生技術等關鍵進展正在加速臨床檢驗。在強大的創業投資和策略夥伴關係關係的支持下，這些公司正在將老化重新定義為一種可治療的疾病，並推動長壽科學和預防性醫療保健領域的模式轉移。

佔比最大的地區：

由於生物技術資金不斷增加、法規不斷簡化以及基礎設施日益完善，預計亞太地區將在預測期內佔據最大市場佔有率。人工智慧驅動的臨床試驗最佳化、表觀遺傳干預和數位健康追蹤等尖端工具正在重塑產業格局。遠距臨床臨床實驗模式和個人化長壽療法等趨勢正在提升參與者的多樣性和參與。關鍵里程碑包括區域臨床試驗標準化、策略合約研究組織 (CRO) 聯盟以及專注於老化的公共衛生措施。這些因素共同推動創新，使該地區成為老齡化研究領域的領導者。

複合年成長率最高的地區：

預計北美將在預測期內實現最高的複合年成長率，這得益於其先進的醫療保健體系、良好的法規結構和雄厚的研究資金。人工智慧試驗管理、精準基因編輯和基於生物標記的生物資訊等技術正在改變試驗方法。分散式模型、靈活的試驗設計以及真實世界數據的整合正在重塑臨床格局。關鍵進展包括FDA批准的衰老研究、不斷擴展的CRO網路以及對神經退化疾病和代謝性疾病的日益關注，這些都鞏固了該地區在抗衰老創新領域的領先地位。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球抗老臨床試驗市場（依治療類型）

  • 老化抑制劑
  • NAD+調變器
  • 基於胜肽的干涉措施
  • 端粒酶活化劑
  • 表觀遺傳重編程劑
  • 幹細胞療法
  • 森諾莫菲克斯
  • 基因治療
  • 其他治療類型

6. 全球抗衰老臨床試驗市場（依試驗階段）

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

7. 全球年齡逆轉臨床試驗市場（依生物標記類型）

  • 基因生物標記
  • 代謝年齡指數
  • 蛋白質體生物標記
  • 發炎標記物
  • 表觀遺傳標記

8. 全球抗老臨床試驗市場（依研究設計）

  • 隨機對照試驗（RCT）
  • 自適應測試
  • 開放標籤研究
  • 分散式/虛擬測試

9. 全球年齡逆轉臨床試驗市場（依目標族群）

  • 健康的老人
  • 患有與老齡化相關的疾病的患者
  • 預防醫學探索者/生物駭客
  • 老年族群

第 10 章。全球年齡逆轉臨床試驗市場（依贊助商類型）

  • 製藥公司
  • 生技公司
  • 政府機構和非營利組織
  • 學術和研究機構

第 11 章。全球年齡逆轉臨床試驗市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：公司概況

  • Altos Labs
  • Oisin Biotechnologies
  • Insilico Medicine
  • FoxBio
  • Calico Life Sciences
  • AgeX Therapeutics
  • Juvenescence
  • Amazentis
  • Life Biosciences
  • Deep Longevity
  • Rejuvenate Bio
  • NewLimit
  • Unity Biotechnology
  • Elysium Health
  • BioAge Labs
  • Cambrian BioPharma
  • Retro Biosciences
  • Turn.bio
Product Code: SMRC30581

According to Stratistics MRC, the Global Age-Reversal Clinical Trials Market is accounted for $1.58 billion in 2025 and is expected to reach $6.38 billion by 2032 growing at a CAGR of 22.0% during the forecast period. Age-Reversal Clinical Trials are scientific studies focused on testing treatments, medications, or interventions intended to decelerate, stop, or reverse biological aging. These trials examine safety, effectiveness, and lasting impacts of approaches like regenerative medicine, senolytics, gene therapies, and lifestyle modifications. By analyzing aging biomarkers, physical performance, and overall wellness, they generate valuable data that may lead to innovations in prolonging healthspan, preventing age-related conditions, and enhancing overall quality of life

According to the National Institute of Health around 7.2 million American citizens aged above 65 and above live with diseases, such as Alzheimer.

Market Dynamics:

Driver:

Growing geriatric population and desire for healthspan extension

The global rise in the aging population is intensifying interest in age-reversal clinical trials. As longevity becomes a central focus, individuals are increasingly seeking interventions that extend not just lifespan but healthspan. This demographic shift is driving demand for therapies that target cellular aging, senescence, and age-related decline. Clinical trials are expanding to explore regenerative medicine, gene therapy, and epigenetic reprogramming. Older adults are more willing to participate in trials that promise improved vitality and reduced disease burden. This convergence of demographic pressure and aspirational aging is accelerating market growth.

Restraint:

Lack of validated biomarkers

Without dependable markers, measuring treatment effectiveness and long-term benefits becomes challenging, complicating trial design, regulatory clearance, and broader clinical use. This lack of standardization makes it difficult to compare findings across different studies, hindering progress. Furthermore, the unavailability of universally recognized biomarkers adds to research expenses, slows therapeutic advancements, and fuels doubts among investors and healthcare professionals, ultimately restricting market expansion and delaying the translation of age-reversal innovations into practical medical solutions.

Opportunity:

Consumer demand for longevity solutions

Public interest in longevity has surged, fueled by media coverage, celebrity endorsements, and the rise of biohacking culture. Consumers are actively seeking age-reversal solutions, from supplements and stem cell therapies to personalized clinical trials. This demand is prompting biotech firms and research institutions to accelerate development pipelines. Direct-to-consumer platforms are emerging to recruit trial participants and offer early access to experimental therapies. As awareness grows, individuals are more willing to invest time and resources into trials that promise rejuvenation. The market is poised to benefit from this groundswell of proactive, health-optimized consumers.

Threat:

Competition from adjacent markets

Age-reversal trials face increasing competition from adjacent sectors such as wellness tech, nutraceuticals, and preventive medicine. These alternatives often promise similar benefits with fewer regulatory hurdles and faster time-to-market. Consumers may opt for non-clinical interventions like wearable health monitors, AI-driven diagnostics, or over-the-counter longevity supplements. This diversion of attention and funding can dilute the clinical trial pipeline and slow innovation. Additionally, cross-sector players are entering the space with hybrid offerings that blur the lines between regulated trials and consumer products. Such competition threatens to fragment the market and challenge the dominance of clinical approaches.

Covid-19 Impact:

The pandemic reshaped the clinical trial landscape, introducing both challenges and opportunities for age-reversal research. Lockdowns and healthcare disruptions delayed trial recruitment and protocol execution. However, the crisis also accelerated interest in immune resilience and biological aging, aligning with age-reversal goals. Remote monitoring tools and decentralized trial models gained traction, enabling broader participation. Telemedicine integration allowed researchers to maintain continuity and collect longitudinal data. Overall, Covid-19 catalyzed innovation in trial design while reinforcing the urgency of age-related health interventions.

The senolytics segment is expected to be the largest during the forecast period

The senolytics segment is expected to account for the largest market share during the forecast period, due to their potential to clear senescent cells that contribute to aging and inflammation. Technological innovations like precision drug delivery, AI-driven molecule discovery, and integrated omics are advancing the field. Trends include the rise of BCL-2 inhibitors, plant-derived compounds, and kinase-targeting agents. Recent progress in trial design and biomarker development is improving clinical outcomes, while increased interest in geroscience is attracting both regulatory attention and biotech investment.

The biotechnology firms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology firms segment is predicted to witness the highest growth rate, through cutting-edge innovations in cellular reprogramming, AI-powered drug discovery, and multi-omics integration. Emerging trends include Yamanaka factor-based rejuvenation, senolytic gene editing, and NAD+ pathway modulation. Key developments such as adaptive trial platforms, precision biomarkers, and organ regeneration technologies are accelerating clinical validation. Backed by robust venture capital and strategic partnerships, these firms are reshaping aging as a treatable condition, fueling a paradigm shift in longevity science and preventive healthcare.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to increased biotech funding, streamlined regulations, and robust infrastructure. Cutting-edge tools like AI-based trial optimization, epigenetic interventions, and digital health tracking are reshaping the landscape. Trends such as remote trial models and tailored longevity treatments are improving participant diversity and engagement. Key milestones include regional trial standardization, strategic CRO alliances, and public health initiatives focused on aging. Together, these elements are driving innovation and positioning the region as a leader in age-reversal research.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by cutting-edge healthcare systems, favourable regulatory frameworks, and substantial research funding. Technologies like AI-enhanced trial management, precision gene editing, and biomarker-based bioinformatics are transforming trial methodologies. The rise of decentralized models, flexible trial designs, and integration of real-world data are reshaping the clinical landscape. Key progress includes FDA-endorsed aging research, expanded CRO networks, and intensified focus on neurodegenerative and metabolic conditions-solidifying the region's role as a frontrunner in age-reversal innovation.

Key players in the market

Some of the key players in Age-Reversal Clinical Trials Market include Altos Labs, Oisin Biotechnologies, Insilico Medicine, FoxBio, Calico Life Sciences, AgeX Therapeutics, Juvenescence, Amazentis, Life Biosciences, Deep Longevity, Rejuvenate Bio, NewLimit, Unity Biotechnology, Elysium Health, BioAge Labs, Cambrian BioPharma, Retro Biosciences, and Turn.bio.

Key Developments:

In June 2025, Insilico Medicine and United Arab Emirates University ("UAEU") have signed a Memorandum of Understanding (MoU) to advance the development of local scientific talents and drive research collaborations within the nation's rapidly growing biotechnology sector.

In May 2024, Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration. Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed.

In January 2022, Altos Labs(TM) launched as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.

Therapy Types Covered:

  • Senolytics
  • NAD+ Modulators
  • Peptide-Based Interventions
  • Telomerase Activators
  • Epigenetic Reprogramming Agents
  • Stem Cell Therapies
  • Senomorphics
  • Gene therapies
  • Other Therapy Types

Trial Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Biomarker Types Covered:

  • Genomic Biomarkers
  • Metabolic Age Indicators
  • Proteomic Biomarkers
  • Inflammatory Markers
  • Epigenetic Markers

Study Designs Covered:

  • Randomized Controlled Trials (RCTs)
  • Adaptive Trials
  • Open-Label Studies
  • Decentralized/Virtual Trials

Target Populations Covered:

  • Healthy Aging Adults
  • Patients with Age-Related Diseases
  • Preventive Health Seekers / Biohackers
  • Geriatric Cohorts

Sponsor Types Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Government & Non-Profit Organizations
  • Academic & Research Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Age-Reversal Clinical Trials Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Senolytics
  • 5.3 NAD+ Modulators
  • 5.4 Peptide-Based Interventions
  • 5.5 Telomerase Activators
  • 5.6 Epigenetic Reprogramming Agents
  • 5.7 Stem Cell Therapies
  • 5.8 Senomorphics
  • 5.9 Gene therapies
  • 5.10 Other Therapy Types

6 Global Age-Reversal Clinical Trials Market, By Trial Phase

  • 6.1 Introduction
  • 6.2 Phase I
  • 6.3 Phase II
  • 6.4 Phase III
  • 6.5 Phase IV

7 Global Age-Reversal Clinical Trials Market, By Biomarker Type

  • 7.1 Introduction
  • 7.2 Genomic Biomarkers
  • 7.3 Metabolic Age Indicators
  • 7.4 Proteomic Biomarkers
  • 7.5 Inflammatory Markers
  • 7.6 Epigenetic Markers

8 Global Age-Reversal Clinical Trials Market, By Study Design

  • 8.1 Introduction
  • 8.2 Randomized Controlled Trials (RCTs)
  • 8.3 Adaptive Trials
  • 8.4 Open-Label Studies
  • 8.5 Decentralized/Virtual Trials

9 Global Age-Reversal Clinical Trials Market, By Target Population

  • 9.1 Introduction
  • 9.2 Healthy Aging Adults
  • 9.3 Patients with Age-Related Diseases
  • 9.4 Preventive Health Seekers / Biohackers
  • 9.5 Geriatric Cohorts

10 Global Age-Reversal Clinical Trials Market, By Sponsor Type

  • 10.1 Introduction
  • 10.2 Pharmaceutical Companies
  • 10.3 Biotechnology Firms
  • 10.4 Government & Non-Profit Organizations
  • 10.5 Academic & Research Institutions

11 Global Age-Reversal Clinical Trials Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Altos Labs
  • 13.2 Oisin Biotechnologies
  • 13.3 Insilico Medicine
  • 13.4 FoxBio
  • 13.5 Calico Life Sciences
  • 13.6 AgeX Therapeutics
  • 13.7 Juvenescence
  • 13.8 Amazentis
  • 13.9 Life Biosciences
  • 13.10 Deep Longevity
  • 13.11 Rejuvenate Bio
  • 13.12 NewLimit
  • 13.13 Unity Biotechnology
  • 13.14 Elysium Health
  • 13.15 BioAge Labs
  • 13.16 Cambrian BioPharma
  • 13.17 Retro Biosciences
  • 13.18 Turn.bio

List of Tables

  • Table 1 Global Age-Reversal Clinical Trials Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Age-Reversal Clinical Trials Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Age-Reversal Clinical Trials Market Outlook, By Senolytics (2024-2032) ($MN)
  • Table 4 Global Age-Reversal Clinical Trials Market Outlook, By NAD+ Modulators (2024-2032) ($MN)
  • Table 5 Global Age-Reversal Clinical Trials Market Outlook, By Peptide-Based Interventions (2024-2032) ($MN)
  • Table 6 Global Age-Reversal Clinical Trials Market Outlook, By Telomerase Activators (2024-2032) ($MN)
  • Table 7 Global Age-Reversal Clinical Trials Market Outlook, By Epigenetic Reprogramming Agents (2024-2032) ($MN)
  • Table 8 Global Age-Reversal Clinical Trials Market Outlook, By Stem Cell Therapies (2024-2032) ($MN)
  • Table 9 Global Age-Reversal Clinical Trials Market Outlook, By Senomorphics (2024-2032) ($MN)
  • Table 10 Global Age-Reversal Clinical Trials Market Outlook, By Gene therapies (2024-2032) ($MN)
  • Table 11 Global Age-Reversal Clinical Trials Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 12 Global Age-Reversal Clinical Trials Market Outlook, By Trial Phase (2024-2032) ($MN)
  • Table 13 Global Age-Reversal Clinical Trials Market Outlook, By Phase I (2024-2032) ($MN)
  • Table 14 Global Age-Reversal Clinical Trials Market Outlook, By Phase II (2024-2032) ($MN)
  • Table 15 Global Age-Reversal Clinical Trials Market Outlook, By Phase III (2024-2032) ($MN)
  • Table 16 Global Age-Reversal Clinical Trials Market Outlook, By Phase IV (2024-2032) ($MN)
  • Table 17 Global Age-Reversal Clinical Trials Market Outlook, By Biomarker Type (2024-2032) ($MN)
  • Table 18 Global Age-Reversal Clinical Trials Market Outlook, By Genomic Biomarkers (2024-2032) ($MN)
  • Table 19 Global Age-Reversal Clinical Trials Market Outlook, By Metabolic Age Indicators (2024-2032) ($MN)
  • Table 20 Global Age-Reversal Clinical Trials Market Outlook, By Proteomic Biomarkers (2024-2032) ($MN)
  • Table 21 Global Age-Reversal Clinical Trials Market Outlook, By Inflammatory Markers (2024-2032) ($MN)
  • Table 22 Global Age-Reversal Clinical Trials Market Outlook, By Epigenetic Markers (2024-2032) ($MN)
  • Table 23 Global Age-Reversal Clinical Trials Market Outlook, By Study Design (2024-2032) ($MN)
  • Table 24 Global Age-Reversal Clinical Trials Market Outlook, By Randomized Controlled Trials (RCTs) (2024-2032) ($MN)
  • Table 25 Global Age-Reversal Clinical Trials Market Outlook, By Adaptive Trials (2024-2032) ($MN)
  • Table 26 Global Age-Reversal Clinical Trials Market Outlook, By Open-Label Studies (2024-2032) ($MN)
  • Table 27 Global Age-Reversal Clinical Trials Market Outlook, By Decentralized/Virtual Trials (2024-2032) ($MN)
  • Table 28 Global Age-Reversal Clinical Trials Market Outlook, By Target Population (2024-2032) ($MN)
  • Table 29 Global Age-Reversal Clinical Trials Market Outlook, By Healthy Aging Adults (2024-2032) ($MN)
  • Table 30 Global Age-Reversal Clinical Trials Market Outlook, By Patients with Age-Related Diseases (2024-2032) ($MN)
  • Table 31 Global Age-Reversal Clinical Trials Market Outlook, By Preventive Health Seekers / Biohackers (2024-2032) ($MN)
  • Table 32 Global Age-Reversal Clinical Trials Market Outlook, By Geriatric Cohorts (2024-2032) ($MN)
  • Table 33 Global Age-Reversal Clinical Trials Market Outlook, By Sponsor Type (2024-2032) ($MN)
  • Table 34 Global Age-Reversal Clinical Trials Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 35 Global Age-Reversal Clinical Trials Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 36 Global Age-Reversal Clinical Trials Market Outlook, By Government & Non-Profit Organizations (2024-2032) ($MN)
  • Table 37 Global Age-Reversal Clinical Trials Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.